Saijo Hajime

OvaScience

OvaScience, Inc. (NASDAQ:OVAS) is a company focused on the discovery and development of new treatment options for women and families struggling with infertility. Each OvaScience treatment is based on the Company's proprietary technology platform that leverages the breakthrough discovery of EggPC cells – immature egg cells found within the outer ovarian cortex. OvaScience is developing OvaPrime, a potential fertility treatment that could help restore a woman's egg production, and OvaTure, a potential fertility treatment that eliminates the need for hormone stimulation. OvaScience's AUGMENT treatment, designed to improve fertilization and pregnancy rates, is available in Japan under an exclusive license to IVF Japan. OvaScience treatments are not available in the United States. For more information, visit www.ovascience.com.